**mRNA therapeutics** deliver messenger RNA to cells, instructing them to produce therapeutic proteins — vaccines, cancer immunotherapies, or replacement enzymes — without altering the genome, with a manufacturing speed and flexibility unprecedented in medicine.

## Overview

The COVID-19 pandemic proved the technology at global scale: BioNTech/Pfizer BNT162b2 and Moderna mRNA-1273 were designed in 48 hours and 13 billion doses were administered, preventing an estimated 20 million deaths. The platform is now being applied across medicine:

**Vaccines**: RSV (Moderna mRESVIA, approved 2023), influenza (universal flu mRNA vaccines in Phase III), HIV (mRNA-1644, Phase I/II). The mRNA vaccine platform can respond to a novel pathogen in days, vs. 6–12 months for conventional vaccines.

**Cancer vaccines**: Personalised mRNA neoantigen vaccines (Moderna + Merck, mRNA-4157/V940) cut melanoma recurrence 44% vs. pembrolizumab alone in Phase IIb (2023) — the first randomised evidence that a personalised cancer vaccine improves survival. Phase III underway in melanoma, lung, and bladder cancer.

**Rare diseases**: mRNA enzyme replacement for OTC deficiency (Arctus), methylmalonic acidemia, and Crigler-Najjar syndrome — diseases where a single deficient enzyme causes catastrophe.

**Cardiology**: anti-PCSK9 mRNA (reduced LDL 50% in Phase I, Moderna) — a potential replacement for lifetime statins.

## Key Actors

Moderna (USD 4.5B cash, mRNA platform pioneer), BioNTech (USD 15B revenue peak, cancer pipeline), CureVac, Translate Bio (Sanofi), Arctus Biotherapeutics, Precision BioSciences, MiNA Therapeutics.

## Economic Value

Global vaccine market: USD 60B/year. mRNA cancer vaccines (highly personalised): USD 100B+/year if approved in multiple cancers. Rare disease enzyme replacement: USD 20B/year. Cardiovascular (anti-PCSK9 mRNA vs. lifetime statins): USD 50B/year addressable. Total mRNA platform potential: USD 200B–500B/year by 2035.

## Notes

Karikó & Weissman won the **Nobel Prize in Physiology or Medicine 2023** for the modified nucleoside chemistry (pseudouridine substitution) that makes mRNA non-immunogenic — the foundational discovery that Karikó's grant applications repeatedly failed to fund in the 1990s–2000s.

## Discovery Character

**Surprise level**: High — nobody expected an mRNA-based vaccine to be the first proven technology for a novel pandemic pathogen. The platform's breadth (vaccines, cancer, rare disease, cardiology) has surprised even its developers.

**Mode**: Systematic-theoretical (RNA biochemistry was well understood) with a key serendipitous enabler: Karikó's modified nucleoside insight was rejected by the mainstream and pursued in obscurity for a decade before COVID demonstrated its value.

## What This Enables

This node is a current frontier — downstream applications (longevity mRNA, in vivo reprogramming) are too speculative for inclusion in this graph yet.